Our study aimed to examine the first‐line ICI efficacy in patients with NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 alterations in a real‐world setting. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.